Volume 14 Supplement 1
Proceedings of Delivery Systems and Current Strategies to Drug Design
Proceedings
Edited by Reinaldo Acevedo, Mario Landys, Armando Acosta, Herve Bercovier, Mohd Nor Norazmi, Valerie Ferro and Maria Elena Sarmiento
Funding of this supplement was supported by Universiti Sains Malaysia, Malaysia and Instituto Finlay, Cuba
Second International Congress on Immunopharmacology 2011. Go to conference site.
Varadero Beach, Cuba26-30 June 2011
-
Citation: BMC Immunology 2013 14(Suppl 1):S1
-
Phage display of functional αβ single-chain T-cell receptor molecules specific for CD1b:Ac2SGL complexes from Mycobacterium tuberculosis-infected cells
The development of molecules specific for M. tuberculosis-infected cells has important implications, as these tools may facilitate understanding of the mechanisms regulating host pathogen interactions in vivo. In...
Citation: BMC Immunology 2013 14(Suppl 1):S2 -
Passive administration of purified secretory IgA from human colostrum induces protection against Mycobacterium tuberculosis in a murine model of progressive pulmonary infection
Immunoglobulin A is the most abundant isotype in secretions from mucosal surfaces of the gastrointestinal, respiratory and genitourinary tracts and in external secretions such as colostrum, breast milk, tears ...
Citation: BMC Immunology 2013 14(Suppl 1):S3 -
Pilot scale production of the vaccine adjuvant Proteoliposome derived Cochleates (AFCo1) from Neisseria meningitidis serogroup B
The use of new adjuvants in vaccine formulations is a subject of current research. Only few parenteral adjuvants have been licensed. We have developed a mucosal and parenteral adjuvant known as AFCo1 (Adjuvant...
Citation: BMC Immunology 2013 14(Suppl 1):S4 -
Immunogenicity of recombinant Mycobacterium bovis bacille Calmette–Guèrin clones expressing T and B cell epitopes of Mycobacterium tuberculosis antigens
Recombinant Mycobacterium bovis bacille Calmette–Guèrin (rBCG) expressing three T cell epitopes of Mycobacterium tuberculosis (MTB) Ag85B antigen (P1, P2, P3) fused to the Mtb8.4 protein (rBCG018) or a combinatio...
Citation: BMC Immunology 2013 14(Suppl 1):S5 -
In silico identification of common epitopes from pathogenic mycobacteria
An in silico study was carried out to identify antigens for their possible collective use as vaccine candidates against diseases caused by different classes of pathogenic mycobacteria with significant clinical...
Citation: BMC Immunology 2013 14(Suppl 1):S6 -
Immunogenicity and cross-reactivity against Mycobacterium tuberculosis of proteoliposomes derived from Mycobacterium bovis BCG
The only currently available vaccine against tuberculosis (TB) is Mycobacterium bovis Bacille Calmette-Guerin (BCG), which has inconsistent efficacy to protect against the disease in adults. M. tuberculosis (MTB)...
Citation: BMC Immunology 2013 14(Suppl 1):S7 -
A proteoliposome formulation derived from Bordetella pertussis induces protection in two murine challenge models
Whooping cough remains a health problem despite high vaccination coverage. It has been recommended that development of new strategies provide long-lasting immunity. The aim of this work was to evaluate the pot...
Citation: BMC Immunology 2013 14(Suppl 1):S8 -
In Silico identification of M. TB proteins with diagnostic potential
TB, caused by Mycobacterium tuberculosis (MTB), is one of the major global infectious diseases. For the pandemic control, early diagnosis with sensitive and specific methods is fundamental. With the advent of bio...
Citation: BMC Immunology 2013 14(Suppl 1):S9 -
Immune adjuvant effect of V. cholerae O1 derived Proteoliposome coadministered by intranasal route with Vi polysaccharide from Salmonella Typhi
The proteoliposome derived from Vibrio cholerae O1 (PLc) is a nanoscaled structure obtained by a detergent extraction process. Intranasal (i.n) administration of PLc was immunogenic at mucosal and systemic level ...
Citation: BMC Immunology 2013 14(Suppl 1):S10 -
Evaluation of specific humoral immune response and cross reactivity against Mycobacterium tuberculosis antigens induced in mice immunized with liposomes composed of total lipids extracted from Mycobacterium smegmatis
The development of a new tuberculosis (TB) vaccine has become one of the main objectives of the scientific community. Protein antigens have been widely explored as subunit TB vaccines, however lipid antigens c...
Citation: BMC Immunology 2013 14(Suppl 1):S11 -
New proteoliposome vaccine formulation from N. meningitidis serogroup B, without aluminum hydroxide, retains its antimeningococcal protectogenic potential as well as Th-1 adjuvant capacity
Proteoliposomes purified from the Outer Membrane of Neisseria meningitidis B, have been successfully used as core for adjuvants and vaccine formulations. We have tried to increase their structural definition and ...
Citation: BMC Immunology 2013 14(Suppl 1):S12 -
Evaluation of the humoral immune response and cross reactivity against Mycobacterium tuberculosis of mice immunized with liposomes containing glycolipids of Mycobacterium smegmatis
Mycobacterium smegmati s (Ms) is a nonpathogenic mycobacteria of rapid growth, which shares many characteristics with Mycobacterium tuberculosis (MTB), the major causative agent of tuberculosis. MTB has several c...
Citation: BMC Immunology 2013 14(Suppl 1):S13
Annual Journal Metrics
-
2022 Citation Impact
3.0 - 2-year Impact Factor
3.6 - 5-year Impact Factor
0.808 - SNIP (Source Normalized Impact per Paper)
0.783 - SJR (SCImago Journal Rank)2023 Speed
26 days submission to first editorial decision for all manuscripts (Median)
188 days submission to accept (Median)2023 Usage
671,800 downloads
176 Altmetric mentions